Onabotulinum Toxin A (Botox) in the Treatment of Transfer Dysphagia
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Dysphagia in patients with stroke, multiple sclerosis, parkinsonism or dystonia can occur due
to relative hypertonia of the cricopharyngeus muscle. In the resting state, muscle is
contracted and relaxes only during deglutition. Treatment of dysphagia by injecting botulinum
toxin in the cricopharyngeus was described by Schneider et al. in 1994. More than 100 cases
have been described after that, however there are no randomized controlled trials. A
meta-analysis from Cochrane has also concluded that there is no sufficient evidence to
conclude regarding the efficacy and safety of Botulinum toxin injection in cricopharyngeal
dysfunction. So this study is necessary to fill this void in knowledge
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
All India Institute of Medical Sciences, New Delhi
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A